Transient left ventricular dysfunction following chimeric antigen receptor T‐cell‐mediated encephalopathy: A form of stress cardiomyopathy. Issue 1 (14th December 2021)

• Record Type: Journal Article
• Authors: Khorasanchi, Adam; Ansari, Amir M.; Bottinor, Wendy; Simmons, Gary; Abbate, Antonio; Toor, Amir A.
• Is Part Of: EJHaem. Volume 3:Issue 1(2022)
• Page Start: 231
• Page End: 234
• Publication Date: 2021-12-14
• Subjects: cardiovascular toxicity -- chimeric antigen receptor T‐cell therapy -- cytokine release syndrome -- diffuse large B‐cell lymphoma -- encephalopathy -- stress cardiomyopathy; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.369
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: Chimeric antigen receptor (CAR) T‐cell therapy represents a new strategy in treating lymphoid malignancies, such as relapsed‐refractory diffuse large B‐cell lymphoma (DLBCL). Several toxicities including cytokine release syndrome (CRS), neurotoxicity, and cardiovascular toxicity have been linked to CAR T‐cell therapy. Transient impairment in left ventricular systolic function is described after CAR‐T, however, the mechanism remains poorly understood. This paper reports the clinical presentation and outcome of two patients with relapsed‐refractory DLBCL who experienced encephalopathy and CRS following CAR T‐cell therapy and developed transient left ventricular dysfunction consistent with stress cardiomyopathy.